title: [Female fertility preservation in autoimmune diseases: possibilities and practises in France].
abstract: Cancer is not the only disease where the question of the female fertility preservation is asked. In autoimmune diseases, alkylating agents are also used and it is now established that 20 g as a cumulative dose of cyclophosphamide is associated with premature ovarian failure in 50% of 20-year-old patients. Several strategies are discussed and offered to these patients to prevent the ovarian failure: GnRH agonist treatment, in vitro fertilization and embryos cryopreservation, oocytes cryopreservation and ovarian cortex cryopreservation. These techniques might also be associated one with the other. A survey was conducted in France in order to assess the practices realised in these diseases. Four centres were asked for these diseases, concerning 17 patients (mean age: 26.2 +/- 1.8 SEM [15-43]) and systemic lupus erythematosus was the most frequent disease (7/17). Ovarian cortex cryopreservation was realised for 6 patients. Embryos or oocytes cryopreservation was realised for 2 patients including one where ovarian cortex cryopreservation was associated. In 10 cases, considering the treatment and the patient's wish no fertility preservation was realised. Female fertility preservation in autoimmune diseases is a difficult question and a national registry, such as the one conducted by the GRECOT, can help to answer this question.
authors: Service de génétique et biologie de la reproduction-CECOS, hôpital Maison-Blanche, 45, rue Cognacq-Jay, 51100 Reims, France. fcarrepigeon@chu-reims.fr
authors: F
authors: F
authors: Carré-Pigeon
authors: B
authors: B
authors: Schubert
mesh_terms: D000328:Adult; D001327:Autoimmune Diseases / Q000150:complications* / Q000188:drug therapy; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D005298:Fertility / Q000502:physiology*; D005602:France; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000517:prevention & control; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced
chemical_list: D003520:Cyclophosphamide